FDA approves pill with digital tracking device you swallow

FDA approves pill with digital tracking device you swallow

In clinical trials for Ability, first approved by the FDA in 2002 to treat schizophrenia, the most common side effects reported by adults were nausea, vomiting, constipation, headache, dizziness, uncontrollable limb and body movements (akathisia), anxiety, insomnia, and restlessness.

Before we have all the answers to those questions, Abilify MyCite is expected to hit the market sometime next year, and for better or worse, the seeds of snitch medication will have been planted.

The technology is meant to help prevent unsafe emergencies that can occur when patients skip their medication, such as manic episodes experienced by those suffering from bipolar disorder.

But developers from Otsuka Pharmaceutical and Proteus Digital Health, who make the sensor, are likely to face hurdles. But the new product will also be labeled with a caveat: There's no evidence that the technology can help patients take their medication as prescribed.

The wearable patch was developed by California-based Proteus Digital Health.

Facebook offers mobile payments in UK
Additionally, Apple has its own Venmo-like money transfer service in the works that's due to be released sometime this fall. Sending and receiving dosh with Messenger sounds like a dawdle, according to Facebook's instructions.

The US Food and Drug Administration (FDA) has approved a drug with an ingestible sensor embedded in it that can record if the medication is ingested or not.

While the technology may seem useful, many are concerned it will lead to a slippery slope of ethical and privacy issues, including law enforcement and insurance agencies monitoring drug usage and adding legal reprimands or additional copays for missed pills, according to The Verge. This signal will be picked up by a patch on the patient's left rib cage, which will then notify the monitoring personnel via the accompanying app. It is also not approved for use in pediatric patients, and may increase suicidal thinking and behavior in children, adolescents, and young adults. "Our rollout of the Abilify MyCite system will be done in phases to obtain, and respond to, feedback from healthcare providers and their patients". The pill has not yet been shown to actually improve patients' medication compliance, a feature insurers are likely to insist on before paying for the pill.

"Abilify MyCite should not be used to track drug ingestion in "real-time" or during an emergency", the statement said, "because detection may be delayed or may not occur". The medication must also be dispensed with a patient Medication Guide with information about the drug's uses and risks.

People often don't take their medications as prescribed. The chronic and severe mental disorder can cause hallucinations, disordered thinking, and delusions, such as hearing voices and believing that other people are reading their minds or spying on them.

The US Centers for Disease Control and Prevention estimates that 6.7% of American adults experienced a major depressive episode in the past 12 months, while lifetime prevalence for bipolar disorder is almost 4% and for schizophrenia almost 1%.

Related Articles